{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T12:41:23Z","timestamp":1795178483687,"version":"4.10.3"},"reference-count":105,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"24","license":[{"start":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T00:00:00Z","timestamp":1671494400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>\n                      <jats:italic toggle=\"yes\">Helicobacter pylori<\/jats:italic>\n                      (\n                      <jats:italic toggle=\"yes\">H. pylori<\/jats:italic>\n                      ) infection is an infectious disease with a prevalence rate of up to 50% worldwide. It can cause indigestion, gastritis, peptic ulcer, and gastric cancer.\n                      <jats:italic toggle=\"yes\">H. pylori<\/jats:italic>\n                      eradication treatment can effectively control disease progression and reduce the risk of the above conditions. However, the escalating trend of antibiotic resistance presents a global challenge for\n                      <jats:italic toggle=\"yes\">H. pylori<\/jats:italic>\n                      eradication. We aim to provide guidance on pharmacological treatment of\n                      <jats:italic toggle=\"yes\">H. pylori<\/jats:italic>\n                      infection.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This clinical practice guideline is developed following the World Health Organization's recommended process, adopting Grading of Recommendations Assessment, Development and Evaluation in assessing evidence quality, and utilizing Evidence to Decision framework to formulate clinical recommendations, minimizing bias and increasing transparency of the clinical practice guideline development process. We used the Reporting Items for practice Guidelines in HealThcare (RIGHT) statement and The Appraisal of Guidelines for Research and Evaluation II (AGREE II) as reporting and conduct guides to ensure the guideline's completeness and transparency.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Though decreasing in developed countries, the prevalence of\n                      <jats:italic toggle=\"yes\">H. pylori<\/jats:italic>\n                      remains high in developing countries, causing a major public health burden. This clinical practice guideline contains 12 recommendations concerning pharmacological treatment for\n                      <jats:italic toggle=\"yes\">H. pylori<\/jats:italic>\n                      eradication. Among them, it is worth highlighting that bismuth preparations are inexpensive, safe, and effective, consequently making bismuth quadruple therapy a preferred choice for initial and rescue treatment. In empirical treatment, high-dose dual therapy is equally effective compared with bismuth quadruple therapy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>The 12 recommendations in this clinical practice guideline are formed with consideration for stakeholders\u2019 values and preferences, resource use, feasibility, and acceptability. Recommendations are generalizable to resource limited settings with similar antibiotic resistance pattern as China, and lower middle-income countries facing comparable sociological and technical challenges.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Registration:<\/jats:title>\n                    <jats:p>Guidelines International Network (GIN) website, https:\/\/guidelines.ebmportal.com\/node\/69996.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/cm9.0000000000002546","type":"journal-article","created":{"date-parts":[[2022,12,29]],"date-time":"2022-12-29T10:00:05Z","timestamp":1672308005000},"page":"2899-2910","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":236,"title":["2022 Chinese national clinical practice guideline on Helicobacter pylori eradication treatment"],"prefix":"10.1097","volume":"135","author":[{"given":"Liya","family":"Zhou","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Peking University Third Hospital, Beijing 100191, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqiang","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Peking University Third Hospital, Beijing 100191, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Lyu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, Zhejiang 310018, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiyao","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Fudan University Affiliated Zhongshan Hospital, Shanghai 200032, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Xia","sequence":"additional","affiliation":[{"name":"Nottingham Ningbo GRADE Center, Nottingham China Health Institute, University of Nottingham Ningbo China, Ningbo, Zhejiang 315100, China"},{"name":"Academic Unit of Lifespan and Population Health, School of Medicine, The University of Nottingham, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhan","family":"Zhao","sequence":"additional","affiliation":[{"name":"Systematic Review Solutions Ltd, Shanghai 201403, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of Helicobacter Pylori Study Group of Chinese Society of Gastroenterology","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,12,20]]},"reference":[{"key":"R1-20250602","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/MCG.0b013e31820fb8f6","article-title":"World gastroenterology organisation global guideline: Helicobacter pylori in developing countries","volume":"45","author":"Organisation","year":"2011","journal-title":"J Clin Gastroenterol"},{"issue":"(Suppl 1)","key":"R2-20250602","article-title":"Epidemiology of Helicobacter pylori infection","volume":"22","author":"Burucoa","year":"2017","journal-title":"Helicobacter"},{"key":"R3-20250602","first-page":"299","article-title":"Helicobacter pylori in developing countries. World Gastroenterology Organisation Global Guideline","volume":"20","author":"Hunt","year":"2011","journal-title":"J Gastrointestin Liver Dis"},{"key":"R4-20250602","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/nrc2857","article-title":"Helicobacter pylori: gastric cancer and beyond","volume":"10","author":"Polk","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"R5-20250602","first-page":"26","article-title":"Epidemiology of gastric cancer: global trends, risk factors and prevention","volume":"14","author":"Rawla","year":"2019","journal-title":"Prz Gastroenterol"},{"key":"R6-20250602","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1093\/jnci\/djs003","article-title":"Fifteen-year effects of Helicobacter pylori, garlic, and vitamin treatments on gastric cancer incidence and mortality","volume":"104","author":"Ma","year":"2012","journal-title":"J Natl Cancer Inst"},{"key":"R7-20250602","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/apt.13497","article-title":"Review article: the global emergence of Helicobacter pylori antibiotic resistance","volume":"43","author":"Thung","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"R8-20250602","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/hel.12242","article-title":"Tailored versus triple plus bismuth or concomitant therapy as initial Helicobacter pylori treatment: a randomized trial","volume":"21","author":"Zhou","year":"2016","journal-title":"Helicobacter"},{"key":"R9-20250602","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/j.dld.2014.08.038","article-title":"Prospective multi-region study on primary antibiotic resistance of Helicobacter pylori strains isolated from Chinese patients","volume":"46","author":"Song","year":"2014","journal-title":"Dig Liver Dis"},{"key":"R10-20250602","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/hel.12046","article-title":"Antibiotic resistance of Helicobacter pylori isolated in the southeast coastal region of China","volume":"18","author":"Su","year":"2013","journal-title":"Helicobacter"},{"key":"R11-20250602","first-page":"655","article-title":"The fourth national consensus report for clinical management of Helicobacter pylori infection (in Chinese)","volume":"32","author":"Liu","year":"2012","journal-title":"Chin J Gastrointerol"},{"key":"R12-20250602","doi-asserted-by":"crossref","first-page":"e12475","DOI":"10.1111\/hel.12475","article-title":"Fifth Chinese national consensus report on the management of Helicobacter pylori infection","volume":"23","author":"Liu","year":"2018","journal-title":"Helicobacter"},{"key":"R14-20250602","doi-asserted-by":"crossref","first-page":"i2089","DOI":"10.1136\/bmj.i2089","article-title":"GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 2: clinical practice guidelines","volume":"353","author":"Alonso-Coello","year":"2016","journal-title":"BMJ"},{"key":"R15-20250602","doi-asserted-by":"crossref","first-page":"E839","DOI":"10.1503\/cmaj.090449","article-title":"AGREE II: advancing guideline development, reporting and evaluation in health care","volume":"182","author":"Brouwers","year":"2010","journal-title":"CMAJ"},{"key":"R16-20250602","doi-asserted-by":"crossref","first-page":"128","DOI":"10.7326\/M16-1565","article-title":"A reporting tool for practice guidelines in health care: the RIGHT statement","volume":"166","author":"Chen","year":"2017","journal-title":"Ann Intern Med"},{"key":"R17-20250602","doi-asserted-by":"crossref","first-page":"460","DOI":"10.22159\/ajpcr.2018.v11i7.24692","article-title":"Clinical evaluation of triple and quadruple Helicobacter pylori eradication therapy in peptic ulcer patients with different ABO blood group phenotypes","volume":"11","author":"Abdulridha","year":"2018","journal-title":"Asian J Pharm Clin Res"},{"key":"R18-20250602","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ajg.2015.09.007","article-title":"Quadruple therapy versus standard triple therapy for eradication of Helicobacter pylori in Kuwait","volume":"16","author":"Alboraie","year":"2015","journal-title":"Arab J Gastroenterol"},{"key":"R19-20250602","first-page":"303","article-title":"A randomized trial comparing four Helicobacter pylori eradication regimens: standard triple therapy, ciprofloxacin based triple therapy, quadruple and sequential therapy","volume":"31","author":"Aminian","year":"2011","journal-title":"Trop Gastroenterol"},{"key":"R20-20250602","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1159\/000236024","article-title":"Bismuth-based first-line therapy for Helicobacter pylori eradication in type 2 diabetes mellitus patients","volume":"82","author":"Demir","year":"2010","journal-title":"Digestion"},{"key":"R21-20250602","doi-asserted-by":"crossref","first-page":"4357","DOI":"10.3748\/wjg.v16.i34.4357","article-title":"Standard triple, bismuth pectin quadruple and sequential therapies for Helicobacter pylori eradication","volume":"16","author":"Gao","year":"2010","journal-title":"World J Gastroenterol"},{"key":"R22-20250602","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1159\/000434627","article-title":"Current status of five different regimens for empiric first-line Helicobacter pylori eradication in Turkey","volume":"92","author":"Gungor","year":"2015","journal-title":"Digestion"},{"key":"R23-20250602","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1159\/000484930","article-title":"Comparison of Helicobacter pylori eradication rates of 2-week levofloxacin-containing triple therapy, levofloxacin-containing bismuth quadruple therapy, and standard bismuth quadruple therapy as a first-line regimen","volume":"26","author":"Kahramano\u011flu Aksoy","year":"2017","journal-title":"Med Princ Pract"},{"key":"R24-20250602","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s12876-021-01680-1","article-title":"Ten-day bismuth-containing quadruple therapy versus 7-day proton pump inhibitor-clarithromycin containing triple therapy as first-line empirical therapy for the Helicobacter pylori infection in Korea: a randomized open-label trial","volume":"21","author":"Kim","year":"2021","journal-title":"BMC Gastroenterol"},{"key":"R25-20250602","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/1751-2980.12679","article-title":"Optimizing first line 7-day standard triple therapy for Helicobacter pylori eradication: prolonging treatment or adding bismuth: which is better?","volume":"19","author":"Leow","year":"2018","journal-title":"J Dig Dis"},{"key":"R26-20250602","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/hel.12052","article-title":"Effect of fluoroquinolone resistance on 14-day levofloxacin triple and triple plus bismuth quadruple therapy","volume":"18","author":"Liao","year":"2013","journal-title":"Helicobacter"},{"key":"R27-20250602","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S1473-3099(19)30272-5","article-title":"Long-term changes of gut microbiota, antibiotic resistance, and metabolic parameters after Helicobacter pylori eradication: a multicentre, open-label, randomised trial","volume":"19","author":"Liou","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"R28-20250602","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1016\/S0140-6736(16)31409-X","article-title":"Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial","volume":"388","author":"Liou","year":"2016","journal-title":"Lancet"},{"key":"R29-20250602","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1007\/s10620-020-06115-7","article-title":"14-day high-dose amoxicillin- and metronidazole-containing triple therapy with or without bismuth as first-line Helicobacter pylori treatment","volume":"65","author":"Luo","year":"2020","journal-title":"Dig Dis Sci"},{"key":"R30-20250602","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/S0140-6736(11)60020-2","article-title":"Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial","volume":"377","author":"Malfertheiner","year":"2011","journal-title":"Lancet"},{"key":"R31-20250602","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ajg.2017.05.002","article-title":"Therapeutic success with bismuth-containing sequential and quadruple regimens in Helicobacter pylori eradication","volume":"18","author":"Ozturk","year":"2017","journal-title":"Arab J Gastroenterol"},{"key":"R32-20250602","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s11684-019-0706-8","article-title":"Is tailored therapy based on antibiotic susceptibility effective? A multicenter, open-label, randomized trial","volume":"14","author":"Pan","year":"2020","journal-title":"Front Med"},{"key":"R33-20250602","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ajg.2012.12.004","article-title":"Penbactam for Helicobacter pylori eradication: a randomised comparison of quadruple and triple treatment schedules in an Iranian population","volume":"14","author":"Seyedmajidi","year":"2013","journal-title":"Arab J Gastroenterol"},{"key":"R34-20250602","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1097\/MAJ.0b013e31819c7320","article-title":"Triple or quadruple tetracycline-based therapies versus standard triple treatment for Helicobacter pylori treatment","volume":"338","author":"Song\u00fcr","year":"2009","journal-title":"Am J Med Sci"},{"key":"R35-20250602","doi-asserted-by":"crossref","first-page":"e5859","DOI":"10.1097\/MD.0000000000005859","article-title":"Efficacy of 1st-line bismuth-containing quadruple therapies with levofloxacin or clarithromycin for the eradication of Helicobacter pylori infection: a 1-week, open-label, randomized trial","volume":"96","author":"Su","year":"2017","journal-title":"Med (Baltimore)"},{"key":"R36-20250602","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ajg.2013.03.002","article-title":"Effect of Helicobacter pylori eradication on glycaemia control in patients with type 2 diabetes mellitus and comparison of two therapeutic regimens","volume":"14","author":"Vafaeimanesh","year":"2013","journal-title":"Arab J Gastroenterol"},{"key":"R37-20250602","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.cmi.2016.12.032","article-title":"Ten-day bismuth-containing quadruple therapy is effective as first-line therapy for Helicobacter pylori-related chronic gastritis: a prospective randomized study in China","volume":"23","author":"Wang","year":"2017","journal-title":"Clin Microbiol Infect"},{"key":"R38-20250602","doi-asserted-by":"crossref","first-page":"5320180","DOI":"10.1155\/2017\/5320180","article-title":"Adding bismuth to rabeprazole-based first-line triple therapy does not improve the eradication of Helicobacter pylori","volume":"2017","author":"Wu","year":"2017","journal-title":"Gastroenterol Res Pract"},{"key":"R39-20250602","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jtcm.2018.02.008","article-title":"Effect of modified Sanhuang Xiexin Tang plus additional herbs combined with","volume":"38","author":"Yao","year":"2018","journal-title":"J Tradit Chin Med"},{"key":"R40-20250602","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/j.1751-2980.2010.00457.x","article-title":"Comparison of the efficacy of triple versus quadruple therapy on the eradication of Helicobacter pylori and antibiotic resistance","volume":"11","author":"Zheng","year":"2010","journal-title":"J Dig Dis"},{"key":"R41-20250602","doi-asserted-by":"crossref","first-page":"e393","DOI":"10.1097\/MJT.0000000000000316","article-title":"A non-inferiority study: modified dual therapy consisting higher doses of rabeprazole is as successful as standard quadruple therapy in eradication of Helicobacter pylori","volume":"24","author":"Sapmaz","year":"2015","journal-title":"Am J Ther"},{"key":"R42-20250602","doi-asserted-by":"crossref","first-page":"275","DOI":"10.4103\/sjg.SJG_91_17","article-title":"Optimized high-dose amoxicillin-proton-pump inhibitor dual therapies fail to achieve high cure rates in China","volume":"23","author":"Hu","year":"2017","journal-title":"Saudi J Gastroenterol"},{"key":"R43-20250602","doi-asserted-by":"crossref","first-page":"437","DOI":"10.14309\/ajg.0000000000000132","article-title":"Eradication efficacy of modified dual therapy compared with bismuth-containing quadruple therapy as a first-line treatment of Helicobacter pylori","volume":"114","author":"Yang","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"R44-20250602","doi-asserted-by":"crossref","first-page":"e12762","DOI":"10.1111\/hel.12762","article-title":"A comparative study of 14-day dual therapy (esomeprazole and amoxicillin four times daily) and triple plus bismuth therapy for first-line Helicobacter pylori infection eradication: a randomized trial","volume":"25","author":"Song","year":"2020","journal-title":"Helicobacter"},{"key":"R45-20250602","doi-asserted-by":"crossref","first-page":"e12768","DOI":"10.1111\/hel.12768","article-title":"The appropriate cutoff gastric pH value for Helicobacter pylori eradication with bismuth-based quadruple therapy","volume":"26","author":"Ke","year":"2021","journal-title":"Helicobacter"},{"key":"R46-20250602","first-page":"11","article-title":"High dose rabeprazole sodium enteric capsules combined with bismuth quadruple therapy for Helicobacter pylori eradication","volume":"15","author":"Ruan","year":"2017","journal-title":"Chin J Prescr Drugs"},{"key":"R47-20250602","doi-asserted-by":"crossref","first-page":"e00432","DOI":"10.1128\/AAC.00432-18","article-title":"Ten-day quadruple therapy comprising low-dose rabeprazole, bismuth, amoxicillin, and tetracycline is an effective and safe first-line treatment for Helicobacter pylori infection in a population with high antibiotic resistance: a prospective, multicenter, randomized, parallel-controlled clinical trial in China","volume":"62","author":"Xie","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"R48-20250602","first-page":"106","article-title":"Helicobacter pylori eradication in people with gastritis and indigestion in Xinjian province (in Chinese)","volume":"9","author":"Yu","year":"2017","journal-title":"Chin J Med Front (Electronic version)"},{"issue":"(suppl1)","key":"R49-20250602","first-page":"e12745","article-title":"Eradication rate of Helicobacter pylori infection in Chinese duodenal ulcer patients treated with vonoprazan 20\u200amg versus lansoprazole 30\u200amg with bismuth containing quadruple therapy","volume":"25","author":"Wang","year":"2020","journal-title":"Helicobacter"},{"key":"R50-20250602","doi-asserted-by":"crossref","first-page":"S197","DOI":"10.1016\/S0016-5085(20)31177-X","article-title":"Phase 3 study evaluating the efficacy and safety of vonoprazan 20\u200amg versus lansoprazole 30\u200amg in the treatment of endoscopically confirmed duodenal ulcers in Asian subjects with or without Helicobacter pylori infection","volume":"158","author":"Hou","year":"2020","journal-title":"Gastroenterology"},{"key":"R51-20250602","doi-asserted-by":"crossref","first-page":"S-531","DOI":"10.1016\/S0016-5085(19)38212-5","article-title":"A phase 1, randomized, double-blind study to evaluate the pharmacokinetics, safety and tolerability of twice daily quadruple therapy containing vonoprazan or lansoprazole in healthy Korean subjects with Helicobacter pylori infection","volume":"156","author":"Chung","year":"2019","journal-title":"Gastroenterology"},{"key":"R52-20250602","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/1751-2980.12934","article-title":"Susceptibility-guided quadruple therapy is not superior to medication history-guided therapy for the rescue treatment of Helicobacter pylori infection: a randomized controlled trial","volume":"21","author":"Ji","year":"2020","journal-title":"J Dig Dis"},{"key":"R53-20250602","doi-asserted-by":"crossref","first-page":"e2056","DOI":"10.1097\/MD.0000000000002056","article-title":"Multiple genetic analysis system-based antibiotic susceptibility testing in Helicobacter pylori and high eradication rate with phenotypic resistance-guided quadruple therapy","volume":"94","author":"Dong","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"R54-20250602","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1111\/apt.15273","article-title":"Randomised controlled trial: susceptibility-guided therapy versus empiric bismuth quadruple therapy for first-line Helicobacter pylori treatment","volume":"49","author":"Chen","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"R55-20250602","first-page":"122","article-title":"Clinical study of Xiangsha Yangwei tablet combined with quadruple therapy in the treatment of Hp infection peptic ulcer (in Chinese)","volume":"51","author":"Chen","year":"2019","journal-title":"J New Chin Med"},{"key":"R56-20250602","first-page":"3206","article-title":"Jinghuaweikang capsules combined with furazolidone-based triple or quadruple therapy as rescue treatment for Helicobacter pylori infection: a multicentre randomised clinical trial (in Chinese)","volume":"96","author":"Cheng","year":"2016","journal-title":"Natl Med J China"},{"key":"R57-20250602","first-page":"1859","article-title":"Ban-Xia-Xie-Xin-Tang-Jia-Wei combined with quadruple therapy for chronic gastritis with unsuccessful Helicobacter pylori eradication (in Chinese)","volume":"41","author":"Hao","year":"2019","journal-title":"Hebei J Chin Med"},{"key":"R58-20250602","first-page":"56","article-title":"Efficacy observation of Lianpuyin combined with quadruple therapy in the treatment of Helicobacter pylori infection-related gastritis (damp-heat syndrome in the spleen and stomach) (in Chinese)","volume":"48","author":"Hua","year":"2016","journal-title":"J New Chin Med"},{"key":"R59-20250602","first-page":"1709","article-title":"Dan-ban-tang for treatment of Helicobacter pylori infection related gastritis (in Chinese)","volume":"40","author":"Huang","year":"2019","journal-title":"Shan-Xi J Chin Med"},{"key":"R60-20250602","first-page":"1130","article-title":"Clinical observation on the treatment of chronic gastritis infected with Helicobacter pylori by combination of traditional Chinese and western medicine (in Chinese)","volume":"37","author":"Huang","year":"2016","journal-title":"Shan-Xi J Chin Med"},{"key":"R61-20250602","first-page":"24","article-title":"Observation on curative effect of Helicobacter pylori positive peptic ulcer treated by integrated traditional Chinese and western medicine (in Chinese)","volume":"34","author":"Li","year":"2018","journal-title":"Shan-Xi J Chin Med"},{"key":"R62-20250602","first-page":"1465","article-title":"Clinical study of Heweiyuyang granule combined with quadruple therapy in the treatment of peptic ulcer associated with Helicobacter pylori mixed with cold and heat (in Chinese)","volume":"40","author":"Lin","year":"2017","journal-title":"Chin J Tradit Med Herbs"},{"key":"R63-20250602","first-page":"3874","article-title":"Clinical study on the application of Jinghua Weikang capsules at different times in the treatment of chronic gastritis infected with Helicobacter pylori (in Chinese)","volume":"21","author":"Luo","year":"2018","journal-title":"Chin J Gen Pract"},{"key":"R64-20250602","first-page":"2060","article-title":"A multi-center randomized controlled study of bismuth quadruple sequential Jinghua Weikang capsules in the treatment of newly diagnosed patients with Helicobacter pylori infection with dyspepsia (in Chinese)","volume":"101","author":"Ma","year":"2021","journal-title":"Natl Med J China"},{"key":"R65-20250602","first-page":"1501","article-title":"The effect of counseling combined with Weikean capsules in the treatment of Hp positive chronic peptic ulcer (in Chinese)","volume":"26","author":"Mei","year":"2018","journal-title":"Chin J Health Psychol"},{"key":"R66-20250602","first-page":"136","article-title":"Clinical observation on Kangyou Heji combined with quadruple therapy treating 25 patients with chronic gastritis with positive Helicobacter pylori (in Chinese)","volume":"57","author":"Wang","year":"2016","journal-title":"J Tradit Chin Med"},{"key":"R67-20250602","first-page":"328","article-title":"Clinical study on the treatment of HP-positive functional dyspepsia of spleen-stomach damp-heat type with modified Sanren decoction combined with quadruple therapy (in Chinese)","volume":"39","author":"Wang","year":"2018","journal-title":"Shan-Xi J Chin Med"},{"key":"R68-20250602","first-page":"1613","article-title":"Ban-Xia-Xie-Xin-Tang-Jia-Wei for treatment of Helicobacter pylori positive peptic ulcer (in Chinese)","volume":"35","author":"Wang","year":"2017","journal-title":"Chin J Tradit Chin Med Pharmacol"},{"key":"R69-20250602","first-page":"122","article-title":"Efficacy evaluation of Jianpi and Weifang combined with quadruple therapy in the treatment of Helicobacter pylori-positive chronic non-atrophic gastritis (in Chinese)","volume":"37","author":"Xie","year":"2020","journal-title":"Chin J Chin Tradit Med Inf"},{"key":"R70-20250602","first-page":"295","article-title":"A prospective multicenter randomized controlled study of bismuth-containing quadruple regimen combined with Jinghua Weikang capsules in the treatment of Helicobacter pylori infection (in Chinese)","volume":"99","author":"Yang","year":"2019","journal-title":"Natl Med J China"},{"key":"R71-20250602","first-page":"55","article-title":"Clinical observation of Longqiweikang tablet combined with quadruple therapy for peptic ulcer (in Chinese)","volume":"47","author":"Ye","year":"2015","journal-title":"N Tradit Chin Med"},{"key":"R72-20250602","first-page":"106","article-title":"Efficacy of self-made Shugan Xierehewei decoction combined with quadruple therapy in the treatment of Hp-positive chronic gastritis and Helicobacter pylori eradication (in Chinese)","volume":"38","author":"Ye","year":"2020","journal-title":"Sichuan J Chin Med"},{"key":"R73-20250602","first-page":"50","article-title":"Clinical observation of curative effect of integrated traditional Chinese and western medicine in the treatment of peptic ulcer associated with Helicobacter pylori (in Chinese)","volume":"39","author":"Zhang","year":"2016","journal-title":"Guang-xi J Tradit Chin Med"},{"key":"R74-20250602","first-page":"119","article-title":"Clinical observation of Qingwei decoction combined with quadruple therapy in the treatment of HP infection (Spleen-stomach damp-heat syndrome) (in Chinese)","volume":"38","author":"Zhang","year":"2020","journal-title":"Sichuan J Chin Med"},{"key":"R75-20250602","first-page":"6","article-title":"Clinical observation on treatment of spleen and stomach deficiency due to Hp-positive chronic gastritis with Tiaozhong Huashi decoction and quadruple therapy (in Chinese)","volume":"42","author":"Zhao","year":"2019","journal-title":"Guang-xi J Tradit Chin Med"},{"key":"R76-20250602","first-page":"164","article-title":"Quadruple therapy combined with Yi-pi-wei-tang for Helicobacter pylori infection related peptic ulcer (in Chinese)","volume":"51","author":"Zhong","year":"2019","journal-title":"J New Chin Med"},{"key":"R77-20250602","first-page":"2053","article-title":"Probiotics improved the effectiveness and safety of the quadruple Helicobacter pylori eradication therapy","volume":"29","author":"Jiang","year":"2018","journal-title":"Biomed Res (India)"},{"key":"R78-20250602","doi-asserted-by":"crossref","first-page":"S-572","DOI":"10.1016\/S0016-5085(20)32137-5","article-title":"Efficacy of probiotics combined with bismuth quadruble therapy on Helicobacter pylori treatment: a randomized controlled study","volume":"158","author":"Liu","year":"2020","journal-title":"Gastroenterology"},{"key":"R79-20250602","first-page":"89","article-title":"Randomized, double-blind, placebo-controlled clinical trial on the usefulness of probiotic Lactobacillus reuteri in bismuth-containing quadruple eradication therapy for infection with Helicobacter pylori","volume":"144","author":"Moreno M\u00e1rquez","year":"2021","journal-title":"Rev Esp Enferm Dig"},{"key":"R80-20250602","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.31557\/APJCP.2019.20.9.2859","article-title":"High effective of 14-day high-dose PPI- bismuth-containing quadruple therapy with probiotics supplement for Helicobacter pylori eradication: a double blinded-randomized placebo-controlled study","volume":"20","author":"Poonyam","year":"2019","journal-title":"Asian Pac J Cancer Prev"},{"key":"R81-20250602","doi-asserted-by":"crossref","first-page":"179","DOI":"10.15171\/mejdd.2016.30","article-title":"The effect of probiotic plus prebiotic supplementation on the tolerance and efficacy of Helicobacter pylori eradication quadruple therapy: a randomized prospective double blind controlled trial","volume":"8","author":"Shafaghi","year":"2016","journal-title":"Middle East J Dig Dis"},{"key":"R82-20250602","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1093\/ajcn\/83.4.864","article-title":"Pretreatment with Lactobacillus- and Bifidobacterium-containing yogurt can improve the efficacy of quadruple therapy in eradicating residual Helicobacter pylori infection after failed triple therapy","volume":"83","author":"Sheu","year":"2006","journal-title":"Am J Clin Nutr"},{"key":"R83-20250602","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s40121-020-00372-9","article-title":"The effect of probiotics supplementation on gut microbiota after Helicobacter pylori eradication: a multicenter randomized controlled trial","volume":"10","author":"Tang","year":"2020","journal-title":"Infect Dis Ther"},{"key":"R84-20250602","first-page":"CR662","article-title":"Effect of Lactobacillus casei supplementation on the effectiveness and tolerability of a new second-line 10-day quadruple therapy after failure of a first attempt to cure Helicobacter pylori infection","volume":"10","author":"Tursi","year":"2004","journal-title":"Med Sci Monit"},{"key":"R85-20250602","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ebiom.2018.08.028","article-title":"The impact of Helicobacter pylori infection, eradication therapy and probiotic supplementation on gut microenvironment homeostasis: an open-label, randomized clinical trial","volume":"35","author":"Chen","year":"2018","journal-title":"EbioMedicine"},{"key":"R86-20250602","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/hel.12047","article-title":"The effects of multistrain probiotic compound on bismuth-containing quadruple therapy for Helicobacter pylori infection: a randomized placebo-controlled triple-blind study","volume":"18","author":"Shavakhi","year":"2013","journal-title":"Helicobacter"},{"key":"R87-20250602","first-page":"1321","article-title":"Effects of addition of probiotic and\/or bismuth to triple therapy of H. pylori and analysis of genetic variation of 23S rRNA gene between patients with clarithromycin sensitivity and resistance","volume":"32","author":"Liu","year":"2019","journal-title":"Pak J Pharm Sci"},{"key":"R88-20250602","doi-asserted-by":"crossref","first-page":"e12659","DOI":"10.1111\/hel.12659","article-title":"Twice-a-day PPI, tetracycline, metronidazole quadruple therapy with Pylera\u00ae or Lactobacillus reuteri for treatment naive or for retreatment of Helicobacter pylori. Two randomized pilot studies","volume":"24","author":"Dore","year":"2019","journal-title":"Helicobacter"},{"key":"R89-20250602","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1111\/hel.12313","article-title":"Rabeprazole, minocycline, amoxicillin, and bismuth as first-line and second-line regimens for Helicobacter pylori eradication","volume":"21","author":"Song","year":"2016","journal-title":"Helicobacter"},{"key":"R90-20250602","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/1751-2980.12334","article-title":"Esomeprazole, minocycline, metronidazole and bismuth as first-line and second-line regimens for Helicobacter pylori eradication","volume":"17","author":"Song","year":"2016","journal-title":"J Dig Dis"},{"key":"R91-20250602","first-page":"1013","article-title":"Application of minocycline-containing quadruple therapy and individualized rescue treatment of Helicobacter pylori infection (in Chinese)","volume":"54","author":"Zhang","year":"2015","journal-title":"Chin J Intern Med"},{"key":"R92-20250602","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.cgh.2013.01.008","article-title":"Efficacy of bismuth-containing quadruple therapies for clarithromycin-, metronidazole-, and fluoroquinolone-resistant Helicobacter pylori infections in a prospective study","volume":"11","author":"Liang","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R93-20250602","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1038\/ajg.2016.443","article-title":"Rescue therapy for Helicobacter pylori eradication: a randomized non-inferiority trial of amoxicillin or tetracycline in bismuth quadruple therapy","volume":"111","author":"Chen","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"R94-20250602","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1056\/NEJMra1807761","article-title":"Penicillin allergy","volume":"381","author":"Castells","year":"2019","journal-title":"N Engl J Med"},{"key":"R95-20250602","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1007\/s11882-014-0476-y","article-title":"Penicillin and beta-lactam allergy: epidemiology and diagnosis","volume":"14","author":"Macy","year":"2014","journal-title":"Curr Allergy Asthma Rep"},{"key":"R96-20250602","doi-asserted-by":"crossref","first-page":"e12686","DOI":"10.1111\/hel.12686","article-title":"Helicobacter pylori first-line and rescue treatments in patients allergic to penicillin: experience from the European Registry on H. pylori management (Hp-EuReg)","volume":"25","author":"Nyssen","year":"2020","journal-title":"Helicobacter"},{"key":"R97-20250602","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s12876-019-1056-3","article-title":"Cefuroxime, levofloxacin, esomeprazole, and bismuth as first-line therapy for eradicating Helicobacter pylori in patients allergic to penicillin","volume":"19","author":"Song","year":"2019","journal-title":"BMC Gastroenterol"},{"key":"R98-20250602","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1007\/s10620-017-4564-4","article-title":"Randomized clinical trial: esomeprazole, bismuth, levofloxacin, and amoxicillin or cefuroxime as first-line eradication regimens for Helicobacter pylori infection","volume":"62","author":"Fu","year":"2017","journal-title":"Dig Dis Sci"},{"key":"R99-20250602","doi-asserted-by":"crossref","first-page":"e12485","DOI":"10.1111\/hel.12485","article-title":"Bismuth improves efficacy of proton-pump inhibitor clarithromycin, metronidazole triple Helicobacter pylori therapy despite a high prevalence of antimicrobial resistance","volume":"23","author":"Long","year":"2018","journal-title":"Helicobacter"},{"key":"R100-20250602","doi-asserted-by":"crossref","first-page":"e12374","DOI":"10.1111\/hel.12374","article-title":"Vonoprazan improves the efficacy of Helicobacter pylori eradication therapy with a regimen consisting of clarithromycin and metronidazole in patients allergic to penicillin","volume":"22","author":"Ono","year":"2017","journal-title":"Helicobacter"},{"key":"R101-20250602","author":"O\u2019Neill","year":"2016","journal-title":"Tackling drug-resistance infections globally: final report and recommendations"},{"key":"R102-20250602","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1136\/gutjnl-2015-311019","article-title":"Role of bismuth in improving Helicobacter pylori eradication with triple therapy","volume":"65","author":"Dore","year":"2016","journal-title":"Gut"},{"key":"R103-20250602","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/S1473-3099(16)30078-0","article-title":"Global leadership against antimicrobial resistance ought to include developing countries","volume":"16","author":"Raut","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"R104-20250602","doi-asserted-by":"crossref","DOI":"10.1136\/gutjnl-2022-327745","article-title":"Management of Helicobacter pylori infection: the Maastricht VI\/Florence consensus report","author":"Malfertheiner","year":"2022","journal-title":"Gut"},{"key":"R105-20250602","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1053\/j.gastro.2018.06.047","article-title":"Efficacies of genotypic resistance-guided vs empirical therapy for refractory Helicobacter pylori infection","volume":"155","author":"Liou","year":"2018","journal-title":"Gastroenterology"},{"key":"R106-20250602","doi-asserted-by":"crossref","first-page":"8","DOI":"10.5009\/gnl20330","article-title":"Treatment of refractory Helicobacter pylori infection-tailored or empirical therapy","volume":"16","author":"Liou","year":"2022","journal-title":"Gut Liver"}],"updated-by":[{"DOI":"10.1097\/cm9.0000000000003134","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,5,5]],"date-time":"2024-05-05T00:00:00Z","timestamp":1714867200000}}],"container-title":["Chinese Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000002546","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T19:08:20Z","timestamp":1748891300000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000002546"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,20]]},"references-count":105,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/cm9.0000000000002546","relation":{},"ISSN":["0366-6999","2542-5641"],"issn-type":[{"value":"0366-6999","type":"print"},{"value":"2542-5641","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,20]]}}}